Welcome to our dedicated page for Grace Therapeutics SEC filings (Ticker: GRCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Grace Therapeutics, Inc. filings document material events, operating updates and governance matters for a late-stage biopharma company advancing GTx-104. Form 8-K disclosures cover quarterly results, corporate presentations, the GTx-104 New Drug Application, the FDA Complete Response Letter, and the chemistry, manufacturing and controls and non-clinical subjects cited in that regulatory correspondence.
The filing record also includes disclosures on patent protection for “Nimodipine Parenteral Administration,” exercises and expirations of common warrants issued in private placements, exhibit-based press releases, and amendments to executive letter agreements and compensation arrangements.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., a ten percent owner, indirectly purchased additional common stock through Opaleye, L.P. The fund bought 9,393 shares on September 8, 2026 at a weighted average price of $2.0972 per share and 5,836 shares on September 9, 2026 at a weighted average price of $2.0899 per share in open-market or private transactions. The prices reflect ranges of $2.095–$2.10 and $2.085–$2.09, respectively, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest; no Rule 10b5-1 trading plan is reported.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli purchased 100,000 shares of common stock on September 9, 2026 in an open-market or private transaction at $2.14 per share. Following this purchase, he directly holds 121,357 shares of Grace Therapeutics common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Grace Therapeutics, Inc. (GRCE) reported that officer Kumar Amresh, VP Program Management, received a grant of stock options for 35,760 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27, with post-grant holdings of 35,760 options.
According to the award terms, the options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting over the following 11 quarters, subject to Mr. Amresh’s continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Medical Officer Macdonald R. Loch received a grant of 54,690 stock options on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27. They vest quarterly over three years, with 1/12 vesting immediately and the remaining 11/12 in equal quarterly installments, subject to continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli received a grant of 267,160 stock options on 2026-08-28. The options have an exercise price of $2.12 per share, expire on 2036-08-27, and relate to 267,160 shares of common stock. According to the vesting terms, 1/12 of the options vested immediately on the grant date and the remaining 11/12 vest in substantially equal quarterly installments over the following 11 quarters, subject to his continuous service.
Grace Therapeutics, Inc. (GRCE) reported that its Principal Financial Officer, Robert J. DelAversano, received a grant of stock options covering 33,660 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27.
These options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting equally over the following 11 quarters, subject to his continuous service. Following this award, he holds 33,660 derivative securities of this type directly.
Grace Therapeutics, Inc. (GRCE) has filed a Form S-3 prospectus to register the resale, from time to time, of up to 4,761,904 shares of common stock by existing selling stockholders. These shares were issued in an August 2026 private placement at $2.10 per share that generated approximately $9.1 million in net proceeds for Grace at closing; the company will receive no cash from subsequent resales.
Grace focuses on reformulating approved drugs for rare and orphan diseases using proprietary drug-delivery technologies and follows the Section 505(b)(2) regulatory pathway. Its pipeline includes three clinical-stage candidates that all hold orphan drug designation, supported by more than 79 granted and pending patents. Lead asset GTx-104, an IV nimodipine formulation for aneurysmal subarachnoid hemorrhage, received an FDA Complete Response Letter in April 2026 citing chemistry, manufacturing and controls, nonclinical items, and the cGMP status of a contract manufacturer, but no clinical safety or efficacy deficiencies.
Grace plans to resubmit the GTx-104 NDA after addressing these issues and has begun a dual-source manufacturing strategy, including technology transfer to a second U.S.-based manufacturer. Following a 2023 strategic realignment, the company is concentrating resources on GTx-104 and, as of June 2026, chose not to resume internal development funding for GTx-102 or GTx-101 under its current operating plan.
Grace Therapeutics, Inc. (GRCE) had a Form 4 filed for Opaleye Management Inc., a more-than-ten-percent holder, reporting an open-market purchase of 11,608 shares of common stock on August 14, 2026 at a weighted average price of $2.0853 per share. The shares are held indirectly by Opaleye, L.P., with Opaleye Management Inc. potentially deemed a beneficial owner through its role as investment manager but disclaiming beneficial ownership except to the extent of its pecuniary interest. Following this transaction, 2,760,000 shares are reported as held indirectly by Opaleye, L.P.
Grace Therapeutics, Inc. received an updated ownership report showing that ADAR1 Capital Management, related entities, and Daniel Schneeberger collectively report beneficial ownership of Grace common stock through prefunded and milestone warrants. ADAR1 Capital Management, LLC and Mr. Schneeberger each report beneficial ownership of 1,806,216 shares of common stock underlying these warrants, representing 9.9% of the company’s common stock based on 16,274,026 shares outstanding as of June 30, 2026. ADAR1 Capital Management GP, LLC reports 1,525,757 underlying shares, or 8.6% of the class.
The filing notes that an additional 69,331 underlying shares are excluded from the reported amounts because exchanges or exercises are subject to a 9.99% beneficial ownership limitation. Mr. Schneeberger is identified as a control person of the ADAR1 investment entities and may be deemed to indirectly beneficially own their reported positions.